Acknowledgements

This project has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

 
About The Innovative Medicines Initiative (IMI):
IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in areas of safety and efficacy, knowledge management and education and training.

 
More information can be found at www.imi.europa.eu